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Abstract
Background: Peripheral arterial disease (PAD), defined by a low ankle-brachial index (ABI), is associated with an
increased risk of cardiovascular events, but the risk of coronary heart disease (CHD) over the range of the ABI is
not well characterized, nor described for African Americans.
Methods: The ABI was measured in 12186 white and African American men and women in the Atherosclerosis
Risk in Communities Study in 1987–89. Fatal and non-fatal CHD events were ascertained through annual telephone
contacts, surveys of hospital discharge lists and death certificate data, and clinical examinations, including
electrocardiograms, every 3 years. Participants were followed for a median of 13.1 years. Age- and field-center-
adjusted hazard ratios (HRs) were estimated using Cox regression models.
Results: Over a median 13.1 years follow-up, 964 fatal or non-fatal CHD events accrued. In whites, the age- and
field-center-adjusted CHD hazard ratio (HR, 95% CI) for PAD (ABI<0.90) was 2.81 (1.77–4.45) for men and 2.05
(1.20–3.53) for women. In African Americans, the HR for men was 4.86 (2.76–8.47) and for women was 2.34 (1.26–
4.35). The CHD risk increased exponentially with decreasing ABI as a continuous function, and continued to decline
at ABI values > 1.0, in all race-gender subgroups. The association between the ABI and CHD relative risk was similar
for men and women in both race groups. A 0.10 lower ABI increased the CHD hazard by 25% (95% CI 17–34%)
in white men, by 20% (8–33%) in white women, by 34% (19–50%) in African American men, and by 32% (17–50%)
in African American women.
Conclusion: African American members of the ARIC cohort had higher prevalences of PAD and greater risk of
CHD associated with ABI-defined PAD than did white participants. Unlike in other cohorts, in ARIC the CHD risk
failed to increase at high (>1.3) ABI values. We conclude that at this time high ABI values should not be routinely
considered a marker for increased CVD risk in the general population. Further research is needed on the value of
the ABI at specific cutpoints for risk stratification in the context of traditional risk factors.
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Background
The ankle-brachial index (ABI) is a simple, non-invasive
measure of subclinical atherosclerosis [1]. Prospective
studies have found that those with ABI-defined peripheral
arterial disease (PAD) are approximately 1.5 to 2 times
more likely to have a clinical CVD event than those with-
out PAD [2-4]. The report of the American Heart Associa-
tion Prevention Conference V concluded that the ABI
provides risk information "over and above that provided
by traditional risk factors" and suggested that the test
"might be a useful addition to the assessment of CHD risk
in selected populations...." [1] Recent guidelines for the
Detection, Evaluation and Treatment of High Blood Cho-
lesterol in Adults (Adult Treatment Panel III) recommend
that an ABI<0.9 be considered a CHD risk equivalent (10-
year CHD risk >20%) [5].
One difficulty in implementing guidelines regarding the
ABI is the lack of a standardized threshold level. Moreo-
ver, in an apparent paradox, several population-based epi-
demiologic studies, including the Atherosclerosis Risk in
Communities (ARIC) study, have found that women have
a lower mean ABI which translates to a higher estimated
prevalence of ABI-defined PAD than men, despite having
lower prevalences of coronary heart disease [6-11].
Women have less intermittent claudication, with a lower
prevalence than men demonstrated in five of six popula-
tion-based epidemiologic studies of the ABI [6-9,12,13],
and with a lower incidence in three of four population-
based epidemiologic studies [14-17]. Some researchers
suggest that gender-specific ABI cutpoints to define PAD
might balance the specificity of this diagnosis in women
and men [6,18,19].
The risk of CHD as a function of the ABI over its entire
range has not been well characterized. The ABI has been
found to have a graded, inverse association with CVD
morbidity and mortality below ABI values considered
"normal"[3,20-22] and to have a U-shaped association
with both all-cause and CVD mortality in American Indi-
ans [23] and in elderly Americans [24]. A lower incidence
of CHD for ABI greater than 1.30 versus ABI 0.90–1.30
was found for African American and white participants of
the Atherosclerosis Risk in Communities (ARIC) study
[25]. While the association of ABI-defined PAD with CHD
risk has been noted for black and white Americans in both
the ARIC study [26] and the Cardiovascular Health Study
[27], to our knowledge the association of the ABI over its
full range with CHD incidence has not been described in
these race groups.
We used 13-year follow-up data from the ARIC study to
compare the relationship between the ABI and incident
CHD between men and women, to estimate the associa-
tions between the ABI and incident CHD in African Amer-
ican and white community residents, and to examine the
association of the entire range of ABI with incident CHD.
Because measurement error may bias these estimates of
association, we also explored the effect of ABI measure-
ment error on these estimates.
Methods
Study population
The ARIC study cohort consists of 15,792 45–64-year-old
members of randomly selected households in four United
States communities: Forsyth County, North Carolina;
northwest suburbs of Minneapolis, Minnesota; Washing-
ton County, Maryland; and black residents of Jackson,
Mississippi. Sampling procedures have been detailed else-
where [28,29]. Each field center's Institutional Review
Board approved the study, and each participant gave
informed consent at each examination. Participants
underwent a baseline clinic examination in 1987–1989,
were examined three more times at approximately 3-year
intervals, and were interviewed annually by telephone.
This report includes follow-up through 2001, with a
median of 13.1 years follow-up. Individuals of race/eth-
nicity other than black or white, and black participants at
Minneapolis and Washington County (n  = 103) were
excluded, because numbers are insufficient for analysis.
Participants with missing baseline ABI (n = 571) or other
covariates (n = 548) were excluded, as were participants
with prevalent CHD (n = 687) or unknown baseline CHD
status (n = 295), leaving for analysis 10028 white and
3650 black participants.
Ankle-brachial index measurement
During an ultrasound exam, trained and certified sonog-
raphers measured ankle and brachial systolic blood pres-
sures with a Dinamap™ 1846 SX automated oscillometric
device (Critikon, Inc, Tampa, Florida). They followed a
standard protocol, using a contour wrapping technique
over the posterior tibial artery at one ankle, selected by the
technician to be the right leg if a random number dis-
played on the computer screen of the work station was
even, and the left leg if odd. Two ankle pressure measure-
ments were taken 5 to 8 minutes apart, while the partici-
pant was in the prone position before and after
undergoing popliteal artery B-mode ultrasound scanning.
Measurements of the brachial blood pressures, usually in
the right brachial, were subsequently taken approximately
every 5 minutes while the participant was in the supine
position undergoing ultrasound scanning of the carotid
artery. The ABI was then calculated as the average of the
two ankle systolic measurements divided by the average of
the first two brachial readings. Two participants who had
missing ABI because readings that were outside the
Dinamap's detection limits (< 30 or > 245 mmHg) were
set to missing. To exclude falsely high ABIs due to arterial
non-compressibility, 10 values where the ankle pressureBMC Cardiovascular Disorders 2007, 7:3 http://www.biomedcentral.com/1471-2261/7/3
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was 75 mmHg or more greater than the arm pressure were
set to missing; this criterion is reported to have 100% pos-
itive predictive value by x-ray for arterial calcification
among diabetic patients, although the sensitivity is low
[30]. The ABI thus defined ranged from 0.43 to 1.83 in the
study population. The reliability coefficient of the ABI
based on single ankle and arm oscillometric blood pres-
sure measurements repeated within 1 year apart has been
estimated from ARIC data to be 0.61; based on data sim-
ulated using ARIC variance estimates, the ratio of the aver-
age of two ankle BPs to the average of two arm BPs has a
reliability coefficient of approximately 0.70 [31].
Covariates
Anthropometry, a fasting blood sample, and a medical
history were taken at the baseline examination. Lipids
were assayed at a central laboratory. Low-density lipopro-
tein (LDL) cholesterol was calculated using the Friede-
wald formula [32], and high-density lipoprotein (HDL)
cholesterol was measured after dextran-magnesium pre-
cipitation of non-HDL lipoproteins. Three seated blood
pressure measurements were taken using a random-zero
sphygmomanometer and the mean of the last two was
used for analysis. Hypertension was defined as sitting
systolic pressure ≥ 140 mmHg, diastolic pressure ≥ 90
mmHg, or the self-reported use of antihypertensive medi-
cation within two weeks prior to the baseline examina-
tion. Diabetes mellitus was defined as a fasting glucose
level ≥ 7.8 mmol/L (140 mg/dL), a non-fasting level ≥
11.1 mmol/L (200 mg/dL), self-reported history of diabe-
tes, or the use of hypoglycemic agents. Intermittent clau-
dication was assessed with the Rose questionnaire [33].
Prevalent CHD was defined as electrocardiographic evi-
dence of a prior myocardial infarction, or a self-reported
history of a physician-diagnosed heart attack, coronary
bypass surgery, or coronary angioplasty. The mean far-
wall carotid intima-medial thickness (IMT) was computed
from B-mode ultrasound measures at three 1-cm seg-
ments of the extra-cranial carotid artery, bilaterally; maxi-
mum likelihood techniques were used to estimate the
mean if any of the six measures were missing [34].
Ascertainment and validation of incident events
Potential incident CHD events were ascertained by annual
telephone participant contacts and by surveys of hospital
discharge lists and death certificate data for potential car-
diovascular events. Trained ARIC personnel abstracted
pertinent data from hospital charts, and copied ECGs for
central reading. Out-of-hospital deaths were investigated
by means of death certificates, interviews with next of kin,
and physician questionnaires, with coroner and autopsy
reports used when available. All potential clinical CHD
events were validated by the ARIC Morbidity and Mortal-
ity Classification Committee using published criteria [28].
Twelve-lead ECGs performed every 3 years at ARIC visits
through 1998 were reviewed to detect unrecognized myo-
cardial infarction (MI), which was defined by the appear-
ance of a major Q-wave or a minor Q-wave with ischemic
ST-T changes, or an MI by computerized NOVACODE cri-
teria [35], confirmed by side-by-side visual comparison of
baseline and follow-up ECGs. Hospitalized MI was classi-
fied as definite or probable based on chest pain symp-
toms, cardiac enzyme or marker levels, and ECG changes.
Definite fatal CHD was classified based on chest pain
symptoms, underlying cause of death, hospital record
information, and medical history. A CHD event was
defined as a definite CHD death, a validated definite or
probable hospitalized MI, or unrecognized MI.
Statistical analysis
Follow-up time was the time between the first ARIC clinic
visit and the first CHD event, or death, last contact date,
or December 31, 2001, whichever came first. For an
unrecognized MI, the follow-up time was estimated as the
midpoint between adjacent visits. Adjusted incidence
rates were computed from Poisson regression. Adjusted
hazard ratios were computed from Cox regression mod-
els. Proportionality of hazards was confirmed by examin-
ing Schoenfeld residuals [36]. Continuous covariates were
entered as linear terms; nonlinearity was examined using
restricted cubic splines [37]. For the ABI, knots for the
restricted cubic spline were placed at the 0.05, 0.35, 0.65,
and 0.95 ABI quantiles in the overall study population
(approximately 0.942, 1.101, 1.193, and 1.346), as rec-
ommended [38]. Categorized ABI variables were also
examined, including categories commonly used to define
peripheral arterial disease (e.g., ABI<0.90). Separate mod-
els were constructed for black and white participants,
where the covariates' effects were allowed to vary by gen-
der. Analyses were performed using SAS release 8.1 (SAS
Institute Inc., Cary, NC). Because regression parameters
may be biased when predictors are measured with error
[39,40], adjustment for ABI measurement error in Cox
regression models was made using a regression calibra-
tion technique [41] and assuming an ABI reliability coef-
ficient of 0.70 [31].
Results
Statistically significant linear associations were found
between increasing ABI and gender, race, age, height,
smoking status, hypertension, diabetes, HDL- and LDL-
cholesterol, and intermittent claudication (Table 1). With
increasing ABI, the mean age and LDL-cholesterol, pro-
portions of African Americans and current smokers, and
proportions with hypertension, diabetes, and intermittent
claudication tended to decrease. HDL-cholesterol and
also mean carotid IMT were lower in those with ABI ≤
0.90. The proportion of men and mean height were
higher in those with ABI ≤ 0.80 and also at ABI levels >
1.20.BMC Cardiovascular Disorders 2007, 7:3 http://www.biomedcentral.com/1471-2261/7/3
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A total of 686 of the 10028 white participants and 278 of
the 3560 African American participants experienced an
incident CHD event. In both men and women and in
whites and African Americans, CHD incidence was higher
for those with ABI-defined PAD than for those without
PAD (Table 2), as has been previously reported for ARIC
data [26]. White men with PAD, defined as an ABI < 0.90,
had an incidence of 21.8 per 1000 person-years, while
those without PAD had an incidence of 8.0 per 1000 per-
son-years. Use of multiple ABI categories revealed an
increase in CHD incidence with decreasing ABI, from 5.7
per 1000 person-years among white men with an ABI
1.20–1.30 to 24.2 per 1000 person-years for those with an
ABI ≤ 0.80. White women with PAD also had a higher
CHD incidence (6.9 per 1000 person-years) than those
without (3.4 per 1000 person-years). Multiple ABI catego-
ries in white women suggested little if any increase in
CHD incidence with ABI decreasing from the category
1.20–1.30 (2.3 per 1000 person-years) to 0.80–0.90 (2.9
per1000 person-years), with a notable increase in CHD
incidence with an ABI ≤ 0.80 (27.1 1000 person-years).
CHD incidence at ABI levels > 1.30 was similar to that esti-
mated for the ABI category 1.20–1.30.
A separate model for African Americans estimated gener-
ally higher CHD incidence rates than for whites and sim-
ilar patterns of increasing CHD risk with decreasing ABI.
African American men with PAD, defined as an ABI <
0.90, had a much higher CHD incidence (40.7 per 1000
person-years) than those without PAD (8.9 per 1000 per-
son-years). African American women with PAD had a
CHD incidence of 11.4 per1000 person-years, and those
without PAD had an incidence of 5.0 per 1000 person-
years.
To explore whether gender differences existed in the asso-
ciation of PAD with incident CHD, race-specific hazard
ratios (HRs) adjusted for age and field center were esti-
mated from Cox regression models (Table 3). In whites,
those with PAD (ABI < 0.90) had twice the hazard of a
CHD event than those without, with a HR of 2.81 for men
and 2.05 for women; there was no statistically significant
effect modification by gender (P = 0.39). In African Amer-
icans, the HR was higher for men (4.86) than for women
(2.34), with marginally statistically significant effect mod-
ification by gender (P = 0.09). As expected, lowering the
ABI cutpoint to define PAD to 0.85 for women increased
the estimated HR to 3.31 in white women and 2.76 in
black women; the statistical significance of the gender dif-
ference in HR decreased in both whites (P = 0.69) and
blacks (P = 0.22).
In both whites and African Americans, modeling the ABI
as ordered categories (Table 3) demonstrated a generally
increasing CHD hazard with decreasing ABI category.
Effect modification of the association of ABI category with
incident CHD by gender was statistically significant in
whites (P = 0.05 whites, P = 0.19 blacks), suggesting a gen-
der difference in the shape of the ABI-CHD risk relation-
ship across the spectrum of ABI up to 1.30.
Modeling these associations in whites and blacks (Figure
1) as smooth curves using restricted cubic spline functions
of the ABI demonstrate generally monotonic increases in
CHD risk with decreasing ABI. Wide confidence intervals
at ABI values < 0.8 (data not shown) reflect the degree of
uncertainty regarding these functions at ABI values of clin-
ical interest. Men and women did not differ significantly
regarding the association of ABI, as a continuous spline
Table 1: Baseline characteristics of participants without prevalent coronary heart disease by ABI category, the ARIC study, 1987–
1989*
Characteristic ≤ 0.80
(N = 124)
(0.80–0.90]
(N = 259)
(0.90–1.00]
(N = 1173)
(1.00–1.10]
(N = 3178)
(1.10–1.20]
(N = 4370)
(1.20–1.30]
(N = 3087)
>1.30
(N = 1397)
P value†
Male, % 50.0 23.6 22.7 32.8 44.6 54.1 59.1 <0.001
African American, % 44.4 28.6 26.7 27.3 26.8 25.0 22.1 <0.001
Age, y 57.3 (5.2) 54.9 (5.9) 53.6 (5.8) 53.6 (5.7) 53.9 (5.7) 54.2 (5.8) 55.0 (5.6) <0.001
Height, cm 167.6 (9.0) 164.9 (8.3) 164.4 (8.2) 166.4 (8.7) 168.8 (9.2) 170.3 (9.4) 171.1 (9.5) <0.001
Smoking status, %
Current smoker 62.9 43.6 32.3 27.1 24.8 22.7 20.8 <0.001
Former smoker 24.2 22.4 27.1 29.3 32.3 35.1 32.5
Never smoker 12.9 34.0 40.6 43.6 42.9 42.2 46.7
Hypertension, % 64.5 41.3 37.2 35.6 32.9 29.2 29.7 <0.001
Diabetes, % 24.2 13.5 10.2 8.6 8.4 7.5 8.6 <0.001
HDL-C, mmol/L 1.22 (0.39) 1.35 (0.45) 1.38 (0.44) 1.40 (0.45) 1.36 (0.45) 1.32 (0.43) 1.30 (0.42) <0.001
LDL-C, mmol/L 3.99 (1.06) 3.67 (1.17) 3.58 (1.03) 3.56 (1.04) 3.52 (1.01) 3.51 (0.98) 3.53 (0.98) 0.017
Carotid IMT, mm§ 0.94 (0.32) 0.79 (0.23) 0.73 (0.20) 0.72 (0.19) 0.71 (0.17) 0.71 (0.16) 0.72 (0.17) 0.47
Rose intermittent claudication, % 11.4 3.1 1.2 0.6 0.5 0.1 0.4 <0.001
*Values are mean (SD) unless otherwise noted. ARIC indicates Atherosclerosis Risk in Communities; HDL-C, HDL-cholesterol; LDL-C, LDL-
cholesterol; ABI, ankle-brachial index; IMT, intima-medial thickness.
†For the test of no rank correlation.BMC Cardiovascular Disorders 2007, 7:3 http://www.biomedcentral.com/1471-2261/7/3
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Table 2: Sample size, number of incident CHD events, and age- and field-center adjusted incidence rates (per 1,000 person-years) by 
gender, race, and ABI level: the ARIC study, 1987–2001*
Men Women
Covariate Sample size CHD events Rate (95% CI) Sample size CHD events Rate (95% CI)
Whites
PAD
ABI < 0.90 80 19 21.8 (13.9 – 34.3) 172 14 6.9 (4.1–11.6)
ABI ≥ 0.90 4446 431 8.0 (7.3–8.9) 5330 222 3.4 (3.0–3.9)
ABI < 0.90 men, < 0.85 women 80 19 21.9 (13.9–34.4) 69 9 11.1 (5.8–21.3)
ABI ≥ 0.90 men, ≥ 0.85 women 4446 431 8.0 (7.3–8.9) 5433 227 3.4 (3.0–3.9)
ABI
≤ 0.80 38 10 24.2 (13.0–45.0) 31 9 27.1 (14.0–52.2)
(0.80–0.90] 43 9 19.5 (10.1–37.6) 142 5 2.9 (1.2–7.0)
(0.90–1.00] 195 27 11.9 (8.2–17.4) 665 35 4.6 (3.3–6.3)
(1.00–1.10] 764 91 10.4 (8.4–12.8) 1546 71 3.9 (3.1–4.9)
(1.10–1.20] 1489 169 9.7 (8.3–11.2) 1712 66 3.1 (2.5–4.0)
(1.20–1.30] 1321 92 5.7 (4.6–7.0) 994 30 2.3 (1.6–3.3)
>1.30 676 52 5.9 (4.5–7.8) 412 20 3.5 (2.3–5.5)
African Americans
PAD
ABI < 0.90 42 14 40.7 (24.0–69.0) 87 11 11.4 (6.3–20.7)
ABI ≥ 0.90 1308 131 8.9 (7.5–10.6) 2123 122 5.0 (4.2–5.9)
ABI < 0.90 men, < 0.85 women 42 14 40.7 (24.0–69.0) 52 8 13.6 (6.8–27.2)
ABI ≥ 0.90 men, ≥ 0.85 women 1308 131 8.9 (7.5–10.6) 2158 125 5.0 (4.2–6.0)
ABI
≤ 0.80 24 6 30.9 (13.8–69.3) 31 7 23.7 (11.3–49.9)
(0.80–0.90] 18 8 52.5 (26.2–105.2) 56 4 6.0 (2.2–16.0)
(0.90–1.00] 71 8 10.5 (5.2–21.0) 242 20 7.6 (4.9–11.8)
(1.00–1.10] 278 34 11.6 (8.3–16.2) 590 46 6.9 (5.2–9.3)
(1.10–1.20] 461 42 8.3 (6.2–11.3) 708 31 3.8 (2.6–5.3)
(1.20–1.30] 349 36 8.7 (6.2–12.0) 423 19 3.9 (2.5–6.1)
>1.30 149 11 6.2 (3.4–11.2) 160 6 2.9 (1.3–6.5)
*Rates are presented at age 55. CHD indicates coronary heart disease; ABI, ankle-brachial index; ARIC, Atherosclerosis Risk in Communities; CI, 
confidence interval; PAD, peripheral arterial disease.
Table 3: Age- and field-center-adjusted CHD incidence hazard ratios for various ABI categories from Cox models for white and 
African American participants: the ARIC study, 1987–2001*
Whites African Americans
Covariate(s) HR*Men (95% CI*) HR Women (95% CI) HR Men (95% CI) HR Women (95% CI)
PAD
ABI < 0.90 2.81 (1.77–4.45) 2.05 (1.20–3.53) 4.86 (2.78–8.47) 2.34 (1.26–4.35)
ABI ≥ 0.90 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
ABI < 0.90 men, < 0.85 women 2.81 (1.77–4.45) 3.31 (1.70–6.45) 4.86 (2.79–8.47) 2.76 (1.35–5.66)
ABI ≥ 0.90 men, ≥ 0.85 women 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
ABI
≤ 0.80 2.39 (1.24–4.60) 7.19 (3.59–14.41) 2.80 (1.16–6.73) 3.60 (1.62–8.00)
(0.80–0.90] 1.94 (0.97–3.84) 0.76 (0.31–1.89) 4.87 (2.25–10.56) 0.87 (0.31–2.41)
(0.90–1.00] 1.15 (0.75–1.77) 1.18 (0.79–1.77) 0.91 (0.42–1.96) 1.10 (0.65–1.86)
(1.00–1.10] 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
(1.10–1.20] 0.93 (0.72–1.20) 0.81 (0.58–1.13) 0.71 (0.45–1.12) 0.54 (0.34–0.85)
(1.20–1.30] 0.54 (0.41–0.73) 0.60 (0.39–0.92) 0.74 (0.46–1.18) 0.56 (0.33–0.95)
> 1.30 0.57 (0.40–0.80) 0.90 (0.55–1.49) 0.53 (0.27–1.04) 0.42 (0.18–0.98)
*CHD, coronary heart disease; ABI, ankle-brachial index; ARIC, Atherosclerosis Risk in Communities; HR, hazard ratio; CI, confidence interval; 
PAD, peripheral arterial disease.BMC Cardiovascular Disorders 2007, 7:3 http://www.biomedcentral.com/1471-2261/7/3
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function, with incident CHD in either whites (P = 0.22) or
African Americans (P = 0.92). Models without the gender-
by-ABI interaction showed that the departure from linear-
ity (on the natural log scale) was not statistically signifi-
cant in either whites (P = 0.12) or blacks (P  = 0.92).
However, in separate models by sex and race, white
women did demonstrate a statistically significant non-
log-linear relationship (P = 0.04). The figure suggests that
the risk of CHD may fail to decline above ABI values of
about 1.2 in this population of white women. Modeled as
a continuous, linear effect, a 0.10 lower ABI increased the
CHD hazard by 25% in white men, by 20% in white
women, by 34% in African American men, and by 32% in
African American women (Table 4). Adjustment for tradi-
tional cardiovascular disease risk factors, excluding hyper-
tension, decreased these hazard ratios by 5 to 9% across
race-sex subgroups. The addition of hypertension among
the risk factors additionally reduced the estimated HRs by
2% or less. Race-specific estimates of the HRs for a 0.1-
unit increase in the ABI, modeled as a linear term, were
increased by about 8% in whites and 14% in blacks after
adjustment for ABI measurement error in models without
covariate adjustment (Table 4). Adjustment for measure-
ment error increased HRs by approximately the same
magnitude in models including age and field center as
covariates, but had slightly less effect in models addition-
ally including cardiovascular risk factors.
Discussion
An ABI less than 0.90 is highly sensitive and specific for
angiographically-diagnosed PAD and it is now well estab-
lished that the risk of a clinical cardiovascular disease
event is increased in those with ABI-defined PAD. A recent
meta-analysis published on behalf of the Ankle Brachial
Index Collaboration [42] that included results from six
general population studies [4,21,43-46] estimated a rela-
Hazard rate ratio (HRR) relative to an ankle-brachial index of 1.0 for incident coronary heart disease (CHD) by gender for  white and African American ARIC participants, 1987–2001 Figure 1
Hazard rate ratio (HRR) relative to an ankle-brachial index of 1.0 for incident coronary heart disease (CHD) by gender for 
white and African American ARIC participants, 1987–2001. White men (A), white women (B), African American men (C), Afri-
can American women (D)
A B
C DBMC Cardiovascular Disorders 2007, 7:3 http://www.biomedcentral.com/1471-2261/7/3
Page 7 of 10
(page number not for citation purposes)
tive risk of 1.45 (95% confidence interval 1.08–1.93) for
fatal or non-fatal CHD associated with an ABI < 0.9. In the
ARIC cohort of 10028 white and 3650 black middle-aged
Americans, the estimated age- and field center-adjusted
HR associated with an ABI < 0.9 for incident CHD was
approximately 2 in all gender-race subgroups except Afri-
can American men. Results of the ARIC study suggest that
the risk of incident CHD may be particularly elevated
among black men with an ABI ≤ 0.9 [26], for whom the
estimated HR was 4.9 (95% CI 2.8–8.5). These results are
of note particularly since African Americans have substan-
tially higher prevalences of PAD and borderline ABI than
non-African Americans as reported in previous studies
[47-52], a pattern also seen in the ARIC population (e.g.,
Table 2).
In all gender-race subgroups of the ARIC cohort of mid-
dle-aged community residents, the ABI had an approxi-
mately log-linear association with CHD risk. This means
that not only did the average CHD risk increase exponen-
tially at values < 1.0, but that CHD risk continued to
decline at ABI values > 1.0. This is in contrast to the U-
shaped association with both all-cause and CVD mortality
reported among American Indians in the Strong Heart
Study [23] and among elderly Medicare recipients in the
Cardiovascular Health Study [24]. Characteristics of ARIC
study [25] and Strong Heart Study [23] participants with
a high ABI and their CVD risk have been described in
detail. Unlike Strong Heart Study participants, ARIC par-
ticipants with an ABI > 1.4 did not have higher levels of
CVD risk factors (e.g., older age, hypertension, triglycer-
ides, LDL-cholesterol) than those with "normal" ABI val-
ues; in both studies, the prevalence of diabetes was not
higher in those with ABI > 1.4 than in those with "nor-
mal" ABI values. While the Strong Heart Study included
participants 45–74 years old, and the Cardiovascular
Health Study included the elderly (≤ 65 years), ARIC par-
ticipants were 45–64 years old at baseline. The ARIC
cohort represents a comparatively healthy, non-institu-
tionalized, middle-aged population with rates of preva-
lent PAD, diabetes, and renal disease reflective of those in
the general population. Thus, a high ABI in the general
population should not be considered as a definite marker
for increased CVD risk, as noted previously [25].
The CHD risk for both white and African American
women in the ARIC study increased notably at ABI levels
< 0.8 and < 0.9 for men, but the small number of events
introduces considerable uncertainty regarding the shape
of the ABI-CHD association at low ABI levels: very few
participants in this middle-aged cohort had an ABI<0.9 (n
= 381) and, therefore, very few CHD events occurred over
13 years in those with an ABI<0.9 (n = 58). There was
some evidence that CHD risk failed to decline at higher
ABI levels in white women, but this pattern was not evi-
dent in the other race-sex subgroups. The lack of a statisti-
cally significant gender difference in the association
between the ABI and the CHD hazard may have been due,
at least in part, to insufficient power. Further analysis of
combined studies such as those undertaken by the Ankle
Brachial Index Collaboration may allow further explora-
tion of these potential differing associations.
Data from ARIC and other studies suggest that the average
risk of future CHD events increases with decreasing ABI as
a continuous, but not linear function. Similar results have
been reported for exertional leg pain [53], for the subclin-
ical burden of atherosclerosis in the popliteal and carotid
arteries [6], and for carotid artery intima-media thickness,
and coronary artery calcium [51]. In the Cardiovascular
Table 4: CHD hazard ratios estimated from Cox regression for a decrement of 0.10 in ABI modelled as a linear, continuous term: 
uncorrected and corrected for ABI reliability
Whites African Americans
Men Women Men Women
Covariates Uncorrected 
HR
(95% CI)
Corrected 
HR
(95% CI)
Uncorrected 
HR
(95% CI)
Corrected 
HR
(95% CI)
Uncorrected 
HR
(95% CI)
Corrected 
HR
(95% CI)
Uncorrected 
HR
(95% CI)
Corrected 
HR
(95% CI)
None 1.24
(1.16–1.33)
1.36
(1.23–1.50)
1.18
(1.06–1.31)
1.27
(1.09–1.47)
1.35
(1.20–1.52)
1.54
(1.30–1.82)
1.34
(1.18–1.52)
1.52
(1.26–1.82)
Age, field center 1.25
(1.17–1.34)
1.39
(1.28–1.54)
1.20
(1.08–1.33)
1.30
(1.12–1.51)
1.34
(1.19–1.50)
1.52
(1.29–1.79)
1.32
(1.17–1.50)
1.49
(1.25–1.78)
Age, field center, 
LDL-C, HDL-C, 
diabetes, smoking 
status
1.17
(1.09–1.26)
1.27
(1.14–1.40)
1.14
(1.03–1.25)
1.20
(1.04–1.39)
1.27
(1.13–1.43)
1.41
(1.19–1.67)
1.20
(1.07–1.35)
1.31
(1.11–1.54)
Age, field center, 
LDL-C, HDL-C, 
diabetes, smoking 
status, hypertension
1.15
(1.08–1.24)
1.24
(1.12–1.37)
1.11
(1.01–1.23)
1.16
(1.01–1.35)
1.25
(1.11–1.41)
1.39
(1.17–1.65)
1.20
(1.07–1.34)
1.30
(1.10–1.53)BMC Cardiovascular Disorders 2007, 7:3 http://www.biomedcentral.com/1471-2261/7/3
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Health Study cohort of older adults, mortality was higher
for ABI values above the conventional cutpoint of 0.90,
relative to the referent category of 1.11 to 1.20, with vari-
ation by age and gender in this association [24]. The
choice of a relevant ABI cutpoint at which risk factor mod-
ification and therapy should be instituted to reduce future
CHD risk is thus unsettled, but should perhaps be based
on models of absolute rather than relative risks of future
CHD events. PAD is identified as a CHD risk equivalent
by the National Cholesterol Education Program (NCEP)
Expert Panel [5] and the ABI is a noninvasive screening
tool that can be performed readily in an office setting. It is
not clear, however, how much information the ABI adds
above and beyond that provided by the traditional risk
factors, at cutpoint values that can guide clinical practice.
Further research should be directed at quantifying the
number of persons who would be identified using the ABI
who would not have otherwise been identified with tradi-
tional risk factors, and the trade-off in the cost of routine
screening, with consideration of relevant cutpoint thresh-
olds.
The variability of the ABI measure was previously reported
to be approximately 12 percent [54]. Adjustment of ABI as
a continuous value for measurement error (i.e., any lack of
repeatability of the measurement protocol used in the
ARIC study [31]) increased estimated multivariable-
adjusted HRs of incident CHD by 8.6% and 5.3% in white
men and women, and by 11.0% and 9.2% in African
American men and women, respectively. Thus, measure-
ment error appears to attenuate the CHD HR estimates for
a 0.1 decrement in the ABI only modestly. However, cate-
gorization of a continuous variable measured with non-
differential error can result in differential misclassification
when the probability of disease is related to the level of
the continuous variable [55]. The possible effect of meas-
urement error on the ABI treated as a dichotomous varia-
ble, therefore, should be considered when examining ABI-
defined PAD, rather than the ABI as a continuous variable,
as a predictor.
Conclusion
African American members of the ARIC cohort had higher
prevalences of PAD and greater risk of CHD associated
with ABI-defined PAD than did white participants. The
risk of CHD increased exponentially with decreasing ABI
in African American and white men and women, and the
association was similar for men and women in both race
groups. Not only did the average CHD risk increase expo-
nentially at values < 1.0 but the risk continued to decline
at ABI values > 1.0. Unlike in other cohorts, in ARIC the
CHD risk failed to increase at high (>1.3) ABI values. We
conclude that at this time high ABI values should not be
routinely considered a marker for increased CVD risk in
the general population. Further research is needed on the
value of the ABI at specific cutpoints for risk stratification
in the context of traditional risk factors.
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